Skip to main content
Erschienen in: Calcified Tissue International 5/2006

01.05.2006 | Clinical Investigations

Loss of Ubiquitin Binding Is a Unifying Mechanism by Which Mutations of SQSTM1 Cause Paget’s Disease of Bone

verfasst von: J. R. Cavey, S. H. Ralston, P. W. Sheppard, B. Ciani, T. R. A. Gallagher, J. E. Long, M. S. Searle, R. Layfield

Erschienen in: Calcified Tissue International | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Ubiquitin-associated (UBA) domain mutations of SQSTM1 are an important cause of Paget’s disease of bone (PDB), which is a human skeletal disorder characterized by abnormal bone turnover. We previously showed that, when introduced into the full-length SQSTM1 protein, the disease-causing P392L, M404V, G411S, and G425R missense mutations and the E396X truncating mutation (representative of all of the SQSTM1 truncating mutations) cause a generalized loss of monoubiquitin binding and impaired K48-linked polyubiquitin binding at physiological temperature. Here, we show that the remaining three known PDB missense mutations, P387L, S399P, and M404T, have similar deleterious effects on monoubiquitin binding and K48-linked polyubiquitin binding by SQSTM1. The P387L mutation affects an apparently unstructured region at the N terminus of the UBA domain, some five residues from the start of the first helix, which is dispensable for polyubiquitin binding by the isolated UBA domain. Our findings support the proposal that the disease mechanism in PDB with SQSTM1 mutations involves a common loss of ubiquitin binding function of SQSTM1 and implicate a sequence extrinsic to the compact globular region of the UBA domain as a critical determinant of ubiquitin recognition by the full-length SQSTM1 protein.
Literatur
1.
Zurück zum Zitat Cody JD, Singer FR, Roodman GD, et al. (1997) Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 61:1117–1122CrossRefPubMed Cody JD, Singer FR, Roodman GD, et al. (1997) Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 61:1117–1122CrossRefPubMed
2.
Zurück zum Zitat Good DA, Busfield F, Fletcher BH, et al. (2001) Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet 70:517–525CrossRefPubMed Good DA, Busfield F, Fletcher BH, et al. (2001) Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet 70:517–525CrossRefPubMed
3.
Zurück zum Zitat Haslam SI, Van Hul W, Morales-Piga A, et al. (1998) Paget’s disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 13:911–917CrossRefPubMed Haslam SI, Van Hul W, Morales-Piga A, et al. (1998) Paget’s disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 13:911–917CrossRefPubMed
4.
Zurück zum Zitat Hocking LJ, Herbert CA, Nicholls RK, et al. (2001) Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet 69:1055–1061CrossRefPubMed Hocking LJ, Herbert CA, Nicholls RK, et al. (2001) Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet 69:1055–1061CrossRefPubMed
5.
Zurück zum Zitat Hughes AE, Shearman AM, Weber JL, et al. (1994) Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum Mol Genet 3:359–361PubMed Hughes AE, Shearman AM, Weber JL, et al. (1994) Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum Mol Genet 3:359–361PubMed
6.
Zurück zum Zitat Laurin N, Brown JP, Lemainque A, et al. (2001) Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528–543CrossRefPubMed Laurin N, Brown JP, Lemainque A, et al. (2001) Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528–543CrossRefPubMed
7.
Zurück zum Zitat Eekhoff EW, Karperien M, Houtsma D, et al. (2004) Familial Paget’s disease in the Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum 50:1650–1654CrossRefPubMed Eekhoff EW, Karperien M, Houtsma D, et al. (2004) Familial Paget’s disease in the Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum 50:1650–1654CrossRefPubMed
8.
Zurück zum Zitat Falchetti A, Di Stefano M, Marini F, et al. (2004) Two novel mutations at exon 8 of Sequestosome 1 gene (SQSTM1) in an Italian serie of patients affected by Paget’s disease of bone (PDB). J Bone Miner Res 19:1013–1017CrossRefPubMed Falchetti A, Di Stefano M, Marini F, et al. (2004) Two novel mutations at exon 8 of Sequestosome 1 gene (SQSTM1) in an Italian serie of patients affected by Paget’s disease of bone (PDB). J Bone Miner Res 19:1013–1017CrossRefPubMed
9.
Zurück zum Zitat Hocking LJ, Lucas GJA, Daroszewska A, et al. (2002) Domain specific mutations in Sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s disease. Hum Mol Genet 11:2735–2739CrossRefPubMed Hocking LJ, Lucas GJA, Daroszewska A, et al. (2002) Domain specific mutations in Sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s disease. Hum Mol Genet 11:2735–2739CrossRefPubMed
10.
Zurück zum Zitat Hocking LJ, Lucas GJA, Daroszewska A, et al. (2004) Novel UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 19:1122–1127CrossRefPubMed Hocking LJ, Lucas GJA, Daroszewska A, et al. (2004) Novel UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 19:1122–1127CrossRefPubMed
11.
Zurück zum Zitat Johnson-Pais TL, Wisdom JH, Weldon KS, et al. (2003) Three novel mutations in SQSTM1 identified in familial Paget’s disease of bone. J Bone Miner Res 18:1748–1753CrossRefPubMed Johnson-Pais TL, Wisdom JH, Weldon KS, et al. (2003) Three novel mutations in SQSTM1 identified in familial Paget’s disease of bone. J Bone Miner Res 18:1748–1753CrossRefPubMed
12.
Zurück zum Zitat Laurin N, Brown JP, Morissette J, Raymond V (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582–1588CrossRefPubMed Laurin N, Brown JP, Morissette J, Raymond V (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582–1588CrossRefPubMed
13.
Zurück zum Zitat Duran A, Serrano M, Leitges M, et al. (2004) The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6:303–309CrossRefPubMed Duran A, Serrano M, Leitges M, et al. (2004) The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6:303–309CrossRefPubMed
14.
Zurück zum Zitat Raasi S, Orlov I, Fleming KG, Pickart CM (2004) Binding of polyubiquitin chains to ubiquitin-associated (UBA) domains of HHR23A. J Mol Biol 341:1367–1379CrossRefPubMed Raasi S, Orlov I, Fleming KG, Pickart CM (2004) Binding of polyubiquitin chains to ubiquitin-associated (UBA) domains of HHR23A. J Mol Biol 341:1367–1379CrossRefPubMed
15.
Zurück zum Zitat Wilkinson CR, Seeger M, Hartmann-Petersen R, et al. (2001) Proteins containing the UBA domain are able to bind to multi-ubiquitin chains. Nat Cell Biol 3:939–943CrossRefPubMed Wilkinson CR, Seeger M, Hartmann-Petersen R, et al. (2001) Proteins containing the UBA domain are able to bind to multi-ubiquitin chains. Nat Cell Biol 3:939–943CrossRefPubMed
16.
Zurück zum Zitat Ciani B, Layfield R, Cavey JR, Sheppard PW, Searle MS (2003) Structure of the UBA domain of p62 (SQSTM1) and implications for mutations which cause Paget’s disease of bone. J Biol Chem 278:37409–37412CrossRefPubMed Ciani B, Layfield R, Cavey JR, Sheppard PW, Searle MS (2003) Structure of the UBA domain of p62 (SQSTM1) and implications for mutations which cause Paget’s disease of bone. J Biol Chem 278:37409–37412CrossRefPubMed
17.
Zurück zum Zitat Shin J (1998) p62 and the sequestosome, a novel mechanism for protein metabolism. Arch Pharm Res 21:629–633PubMedCrossRef Shin J (1998) p62 and the sequestosome, a novel mechanism for protein metabolism. Arch Pharm Res 21:629–633PubMedCrossRef
18.
Zurück zum Zitat Vadlamudi RK, Joung I, Strominger JL, Shin J (1996) p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 271:20235–20237CrossRefPubMed Vadlamudi RK, Joung I, Strominger JL, Shin J (1996) p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 271:20235–20237CrossRefPubMed
19.
Zurück zum Zitat Kanayama A, Seth RB, Sun L, et al. (2004) TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 15:535–548CrossRefPubMed Kanayama A, Seth RB, Sun L, et al. (2004) TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 15:535–548CrossRefPubMed
20.
Zurück zum Zitat Layfield R, Hocking LJ (2004) SQSTM1 and Paget’s disease of bone. Calcif Tissue Int 75:347–357CrossRefPubMed Layfield R, Hocking LJ (2004) SQSTM1 and Paget’s disease of bone. Calcif Tissue Int 75:347–357CrossRefPubMed
21.
Zurück zum Zitat Wooten MW, Geetha T, Seibenhener ML, et al. (2005) The p62 scaffold regulates NGF-induced NF-kappa B activation by influencing TRAF6 polyubiquitination. J Biol Chem 280:35625–35629CrossRefPubMed Wooten MW, Geetha T, Seibenhener ML, et al. (2005) The p62 scaffold regulates NGF-induced NF-kappa B activation by influencing TRAF6 polyubiquitination. J Biol Chem 280:35625–35629CrossRefPubMed
22.
Zurück zum Zitat Cavey JR, Ralston SH, Hocking LJ, et al. (2005) Loss of ubiquitin-binding associated with Paget’s disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 20:619–624CrossRefPubMed Cavey JR, Ralston SH, Hocking LJ, et al. (2005) Loss of ubiquitin-binding associated with Paget’s disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 20:619–624CrossRefPubMed
23.
Zurück zum Zitat Thrower JS, Hoffman L, Rechsteiner M, Pickart CM (2000) Recognition of the polyubiquitin proteolytic signal. EMBO J 19:94–102CrossRefPubMed Thrower JS, Hoffman L, Rechsteiner M, Pickart CM (2000) Recognition of the polyubiquitin proteolytic signal. EMBO J 19:94–102CrossRefPubMed
24.
Zurück zum Zitat Mueller TD, Feigon J (2002) Solution structures of UBA domains reveal a conserved hydrophobic surface for protein-protein interactions. J Mol Biol 319:1243–1255CrossRefPubMed Mueller TD, Feigon J (2002) Solution structures of UBA domains reveal a conserved hydrophobic surface for protein-protein interactions. J Mol Biol 319:1243–1255CrossRefPubMed
25.
Zurück zum Zitat Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649CrossRefPubMed Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649CrossRefPubMed
26.
Zurück zum Zitat Babu JR, Geetha T, Wooten MW (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94:192–203CrossRefPubMed Babu JR, Geetha T, Wooten MW (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94:192–203CrossRefPubMed
27.
Zurück zum Zitat Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24:8055–8068CrossRefPubMed Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24:8055–8068CrossRefPubMed
28.
Zurück zum Zitat Raasi S, Varadan R, Fushman D, Pickart CM (2005) Diverse polyubiquitin interaction properties of ubiquitin-associated domains. Nat Struct Mol Biol 12:708–714CrossRefPubMed Raasi S, Varadan R, Fushman D, Pickart CM (2005) Diverse polyubiquitin interaction properties of ubiquitin-associated domains. Nat Struct Mol Biol 12:708–714CrossRefPubMed
29.
Zurück zum Zitat Raasi S, Pickart CM (2003) Rad23 ubiquitin-associated domains (UBA) inhibit 26 S proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains. J Biol Chem 278:8951–8959CrossRefPubMed Raasi S, Pickart CM (2003) Rad23 ubiquitin-associated domains (UBA) inhibit 26 S proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains. J Biol Chem 278:8951–8959CrossRefPubMed
30.
Zurück zum Zitat Walters KJ, Lech PJ, Goh AM, Wang Q, Howley PM (2003) DNA-repair protein hHR23a alters its protein structure upon binding proteasomal subunit S5a. Proc Natl Acad Sci USA 100:12694–12699CrossRefPubMed Walters KJ, Lech PJ, Goh AM, Wang Q, Howley PM (2003) DNA-repair protein hHR23a alters its protein structure upon binding proteasomal subunit S5a. Proc Natl Acad Sci USA 100:12694–12699CrossRefPubMed
31.
Zurück zum Zitat Merkley N, Shaw GS (2004) Solution structure of the flexible class II ubiquitin-conjugating enzyme Ubc1 provides insights for polyubiquitin chain assembly. J Biol Chem 279:47139–47147CrossRefPubMed Merkley N, Shaw GS (2004) Solution structure of the flexible class II ubiquitin-conjugating enzyme Ubc1 provides insights for polyubiquitin chain assembly. J Biol Chem 279:47139–47147CrossRefPubMed
Metadaten
Titel
Loss of Ubiquitin Binding Is a Unifying Mechanism by Which Mutations of SQSTM1 Cause Paget’s Disease of Bone
verfasst von
J. R. Cavey
S. H. Ralston
P. W. Sheppard
B. Ciani
T. R. A. Gallagher
J. E. Long
M. S. Searle
R. Layfield
Publikationsdatum
01.05.2006
Erschienen in
Calcified Tissue International / Ausgabe 5/2006
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-005-1299-6

Weitere Artikel der Ausgabe 5/2006

Calcified Tissue International 5/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.